Chengdu Kanghong Pharmaceutical Group (002773.SZ)"KH812 Intraocular Injection" Clinical Trial Approved.

Chengdu Kanghong Pharmaceutical Group (002773.SZ) announced that its wholly-owned subsidiary Chengdu Kanghong Biotechnology Co., Ltd. (hereinafter referred to as "Kanghong Biotechnology") has received a "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration for its product: "KH812 Intravitreal Injection". KH812 Intravitreal Injection is a biosimilar drug developed by Kanghong Biotechnology, which specifically binds to vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PlGF), blocking the activity of VEGF-A and PlGF, effectively interfering with the increase in vascular permeability, the generation of new blood vessels, and the occurrence of vascular inflammation, thereby inhibiting or alleviating symptoms such as retinal edema, ischemia, and bleeding.